European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme

Additional Metadata
Keywords	Chemotherapy, Glioblastoma multiforme, Glufosfamide, Recurrent
Persistent URL	doi.org/10.1093/annonc/mdg491, hdl.handle.net/1765/71024
Journal	Annals of Oncology
Organisation	Department of Neurology
Citation APA APA Style APA-ALL Style AAA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	van den Bent, M., Grisold, W., Frappaz, D., Stupp, R., Desir, J. P., Lesimple, T., Dittrich, C., de Jonge, M., Brandes, A., Frenay, M., Carpentier, A., Chollet, P., Oliveira, J., Baron, B., Lacombe, D., Schuessler, M.& Fumoleau, P. (2003). European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. Annals of Oncology, 14(12), 1732–1734.https://doi.org/10.1093/annonc/mdg491

Publication